Stimulated thyroglobulin at recombinant human TSH-aided ablation predicts disease-free status one year later
- PMID: 24037891
- DOI: 10.1210/jc.2013-2267
Stimulated thyroglobulin at recombinant human TSH-aided ablation predicts disease-free status one year later
Abstract
Context: Thyroglobulin (Tg) levels measured at the time of remnant ablation after thyroid hormone withdrawal (THW) were shown to have prognostic value in predicting disease-free status.
Objectives: Our objectives were to determine whether stimulated Tg levels, measured at the time of remnant ablation performed under recombinant human TSH (rhTSH) stimulation, has value in predicting absence of detectable disease 1 year after radioiodine therapy and to compare the results obtained with this approach with a cohort of patients submitted to ablation after THW.
Design: This was a prospective observational study.
Setting and patients: The study included 293 consecutive patients treated for a differentiated thyroid carcinoma with no initial evidence of distant metastasis. All patients were submitted to a total or near-total thyroidectomy, followed by ablation either under rhTSH (n = 151) or endogenous TSH stimulation (n = 142). Patients with positive Tg antibodies were excluded.
Main outcome measures: The predictive value of Tg at ablation was assessed by receiver operating characteristic curve analysis.
Results: In the rhTSH group, 96 patients (73.3%) were considered disease-free at 1 year. Stimulated Tg at ablation after rhTSH was found to be an independent prognostic indicator of disease persistence 12 months later. The highest-accuracy cutoff value for absence of detectable disease was defined as 7.2 ng/mL, with a negative predictive value of 90%. In the THW group, Tg at ablation also proved to have independent predictive value. Using the same threshold (7.2 ng/mL), the negative predictive value of Tg was 95% in the THW group.
Conclusions: When rhTSH was used, stimulated Tg at ablation had independent predictive value for disease-free status 1 year later. A low stimulated Tg at rhTSH-aided ablation may be considered a favorable prognosis factor.
Similar articles
-
Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.Endocrine. 2017 Jan;55(1):200-208. doi: 10.1007/s12020-016-1104-5. Epub 2016 Sep 21. Endocrine. 2017. PMID: 27655291
-
Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis.Radiother Oncol. 2014 Jan;110(1):25-30. doi: 10.1016/j.radonc.2013.12.018. Epub 2014 Jan 28. Radiother Oncol. 2014. PMID: 24485353 Review.
-
Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.Clin Endocrinol (Oxf). 2008 Oct;69(4):659-63. doi: 10.1111/j.1365-2265.2008.03244.x. Epub 2008 Mar 18. Clin Endocrinol (Oxf). 2008. PMID: 18363882
-
A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later.J Clin Endocrinol Metab. 2005 Sep;90(9):5047-57. doi: 10.1210/jc.2005-0492. Epub 2005 Jun 21. J Clin Endocrinol Metab. 2005. PMID: 15972576
-
Follow-up of differentiated thyroid carcinoma.Minerva Endocrinol. 2004 Dec;29(4):161-74. Minerva Endocrinol. 2004. PMID: 15765026 Review. English, Italian.
Cited by
-
Radioactive iodine therapy for follicular thyroid cancer: a 15 years follow-up study of Chinese patients.Nucl Med Commun. 2024 Mar 1;45(3):169-174. doi: 10.1097/MNM.0000000000001798. Epub 2023 Dec 14. Nucl Med Commun. 2024. PMID: 38095140 Free PMC article.
-
Is radioiodine ablation with 1.1 GBq (30 mCi) 131I necessary in low-risk thyroid cancer patients? Results from a long-term follow-up prospective study.Endocrine. 2023 Jun;80(3):606-611. doi: 10.1007/s12020-023-03306-w. Epub 2023 Mar 29. Endocrine. 2023. PMID: 36988853
-
2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?Eur Thyroid J. 2022 Jan 1;11(1):e210046. doi: 10.1530/ETJ-21-0046. Eur Thyroid J. 2022. PMID: 34981741 Free PMC article.
-
Intermediate-risk thyroid carcinoma: indicators of a poor prognosis.Arch Endocrinol Metab. 2021 May 18;64(6):764-771. doi: 10.20945/2359-3997000000290. Arch Endocrinol Metab. 2021. PMID: 34033287 Free PMC article.
-
Dynamic Risk Stratification for Predicting Treatment Response in Differentiated Thyroid Cancer.J Clin Med. 2020 Aug 21;9(9):2708. doi: 10.3390/jcm9092708. J Clin Med. 2020. PMID: 32825789 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous